Source:http://linkedlifedata.com/resource/pubmed/id/17510372
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
9
|
pubmed:dateCreated |
2007-8-20
|
pubmed:abstractText |
Cortactin and fascin-1 are important factors in tumor progression. We tested the hypothesis that cortactin and fascin-1 expression correlates with clinicopathological parameters of gastric adenocarcinoma. Immunohistochemical analysis of cortactin and fascin-1 was done using tissue microarrays of 100 surgical specimens, including 20 well-differentiated, 20 moderately differentiated, and 60 poorly differentiated gastric adenocarcinomas. Among the 20 well-differentiated gastric adenocarcinomas, 15 cases (75%) showed negative or weak staining (1+); 5 cases (25%) had moderate (2+) or strong (3+) cortactin expression. Among the 60 poorly differentiated gastric adenocarcinomas, more than three-quarters of the cases (76.7%) had moderate or strong cortactin expression; 14 cases (23.3%) had weak staining. Of 20 well-differentiated gastric adenocarcinoma cases, 14 (70%) showed negative or weak staining of fascin-1, whereas nearly one-third (30%) had moderate or strong expression. Among the 60 poorly differentiated gastric adenocarcinomas, 32 (53.3%) exhibited moderate or strong fascin-1 expression; fewer than half of the cases showed negative or weak staining. Higher intensity of cortactin and fascin-1 staining correlated directly with more-advanced cancer stages (TNM) and inversely with survival rates. Our findings suggest the possibility that pharmacological inhibitors of cortactin and fascin-1 activity may slow down tumor progression and prolong survival time in patients with gastric adenocarcinomas.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
0022-1554
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
55
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
955-62
|
pubmed:meshHeading |
pubmed-meshheading:17510372-Adenocarcinoma,
pubmed-meshheading:17510372-Carrier Proteins,
pubmed-meshheading:17510372-Cortactin,
pubmed-meshheading:17510372-Female,
pubmed-meshheading:17510372-Humans,
pubmed-meshheading:17510372-Immunohistochemistry,
pubmed-meshheading:17510372-Male,
pubmed-meshheading:17510372-Microfilament Proteins,
pubmed-meshheading:17510372-Neoplasm Staging,
pubmed-meshheading:17510372-Stomach Neoplasms,
pubmed-meshheading:17510372-Survival Rate,
pubmed-meshheading:17510372-Tissue Array Analysis
|
pubmed:year |
2007
|
pubmed:articleTitle |
Association of cortactin and fascin-1 expression in gastric adenocarcinoma: correlation with clinicopathological parameters.
|
pubmed:affiliation |
Department of Pathology, Tri-Service General Hospital, National Defense Medical Center, Neihu, Taipei, Taiwan.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|